Erenumab for episodic migraine
Source : https://www.futuremedicine.com/doi/10.2217/pmt-2021-0077
In this review, the authors provide an overview of erenumab, a monoclonal antibody used for the preventative treatment of episodic migraine by targeting the CGRP pathway. Randomized controlled trials have...
Conclusion/Relevance: In this review, the authors provide an overview of erenumab, a monoclonal antibody used for the preventative treatment of episodic migraine by targeting the CGRP pathway. Randomized controlled trials have shown that erenumab is associated with a statistically significant decrease in monthly migraine days in patients with...
Exploring the contributing factors to multiple chemical sensitivity in patients with migraine - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35363938/
doi: 10.1002/1348-9585.12328. 1 Department of Neurology, Dokkyo Medical University, Tochigi, Japan. 2 Integrated Research Faculty for Advanced Medical Science, Dokkyo Medical University School of Medicine, Tochigi, Japan. 3 Department of...
Conclusion: We showed that MCS was observed in 20% of patients with migraine, and our study results may indicate a possible association of MCS with central sensitization and hypersensitivity-related symptoms in patients with migraine.
-
Migraine Connect3yrKey Points • Source: Journal of Occupational Health • Conclusion/Relevance: “We showed that MCS [multiple chemical sensitivity] was observed in 20% of patients with migraine, and our study results may indicate a Show More
Association between patent foramen ovale and migraine without aura: a community-based cross-sectional study in China
Source : https://bmjopen.bmj.com/content/12/3/e056937
Objectives To assess the influence of patent foramen ovale (PFO) on the prevalence of migraine without aura based on propensity score-matched samples in Southwest China. Design Propensity-matched cross-sectional study. Participants...
Conclusion:This community-based cross-sectional study pointed to a strong association between PFO and migraine without aura, especially when the shunt is large.
Erenumab for episodic migraine - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35313740/
In this review, the authors provide an overview of erenumab, a monoclonal antibody used for the preventative treatment of episodic migraine by targeting the CGRP pathway. Randomized controlled trials have...
Conclusions: Erenumab faces significant limitations because of its high financial cost. Additional long-term real-world data are needed to understand the role of erenumab in the treatment of migraine.
Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience - The Journal of Headache and Pain
Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01417-9
Background Migraine frequency increases after the cessation of successful preventive treatment with CGRP(-receptor) monoclonal antibodies (mAbs). In this study, we aimed to evaluate the course of migraine after treatment resumption....
Conclusions: Reinitiation of treatment with CGRP(-R) mAbs after a drug holiday leads to a significant reduction of migraine frequency and medication use as well as improvement in quality of life.
Gmail
Source : https://accounts.google.com
Gmail is email that's intuitive, efficient, and useful. 15 GB of storage, less spam, and mobile access.